242 related articles for article (PubMed ID: 3052962)
1. Renal osteodystrophy and aluminum bone disease in CAPD patients.
Gokal R
Clin Nephrol; 1988; 30 Suppl 1():S64-7. PubMed ID: 3052962
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
4. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
Weinreich T; Ritz E; Passlick-Deetjen J
Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
[TBL] [Abstract][Full Text] [Related]
5. Mineral metabolism and renal bone disease: effects of CAPD versus hemodialysis.
Coburn JW
Kidney Int Suppl; 1993 Feb; 40():S92-100. PubMed ID: 8445845
[No Abstract] [Full Text] [Related]
6. [Renal osteodystrophy (3); its treatment in dialysis patients].
Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
[TBL] [Abstract][Full Text] [Related]
7. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group.
Weinreich T; Passlick-Deetjen J; Ritz E
Am J Kidney Dis; 1995 Mar; 25(3):452-60. PubMed ID: 7872324
[TBL] [Abstract][Full Text] [Related]
8. Control of mineral metabolism in CAPD patients.
Delmez JA
Blood Purif; 1989; 7(2-3):167-80. PubMed ID: 2663036
[TBL] [Abstract][Full Text] [Related]
9. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
Hottelart C; Bako G; Oprisiu R; Georgita A; Presne C; Sarraj A; Morinière P; el Esper N; Fournier A
Nephrologie; 2000; 21(6):275-82. PubMed ID: 11117106
[TBL] [Abstract][Full Text] [Related]
10. [Renal osteodystrophy in dialysis patients as estimated by three-point bone densitometry].
Kucharska E; Stompór T; Sułowicz W; Drozdz M; Kaczmarczyk I; Szymczakiewicz-Multanowska A; Chruściel B; Kraśnicka M
Przegl Lek; 2000; 57(6):334-9. PubMed ID: 11107868
[TBL] [Abstract][Full Text] [Related]
11. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
[TBL] [Abstract][Full Text] [Related]
12. Renal osteodystrophy in CAPD.
Hutchison AJ; Freemont AJ; Lumb GA; Gokal R
Adv Perit Dial; 1991; 7():237-9. PubMed ID: 1680434
[TBL] [Abstract][Full Text] [Related]
13. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
Navarro JF; Mora C; Macia M; Garcia J
Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
[TBL] [Abstract][Full Text] [Related]
14. Controlled study of renal osteodystrophy in patients undergoing dialysis. Improved response to continuous ambulatory peritoneal dialysis compared with hemodialysis.
Shusterman NH; Wasserstein AG; Morrison G; Audet P; Fallon MD; Kaplan F
Am J Med; 1987 Jun; 82(6):1148-56. PubMed ID: 3605132
[TBL] [Abstract][Full Text] [Related]
15. Alternative phosphate binders in dialysis patients: calcium carbonate.
Slatopolsky E; Weerts C; Stokes T; Windus D; Delmez J
Semin Nephrol; 1986 Dec; 6(4 Suppl 1):35-41. PubMed ID: 3602677
[TBL] [Abstract][Full Text] [Related]
16. Calcium concentration in the CAPD dialysate: what is optimal and is there a need to individualize?
Bro S; Brandi L; Daugaard H; Olgaard K
Perit Dial Int; 1997; 17(6):554-9. PubMed ID: 9655154
[TBL] [Abstract][Full Text] [Related]
17. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
Bro S; Brandi L; Olgaard K
Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
[TBL] [Abstract][Full Text] [Related]
18. Hysteresis of the parathyroid hormone response to hypocalcemia in hemodialysis patients with low turnover aluminum bone disease.
Felsenfeld AJ; Ross D; Rodriguez M
J Am Soc Nephrol; 1991 Dec; 2(6):1136-43. PubMed ID: 1777594
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral and aluminum concentrations in patients undergoing CAPD.
Giangrande A; Costanini S; Ballanti P; Castiglioni A; Caligara F; Pisoni B; Giordano R; Vernillo I; Berni S; Bonucci E
Adv Perit Dial; 1992; 8():351-5. PubMed ID: 1361821
[TBL] [Abstract][Full Text] [Related]
20. Calcium and phosphorus in diet therapy of uremia.
Schoolwerth AC; Engle JE
J Am Diet Assoc; 1975 May; 66(5):460-4. PubMed ID: 1123506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
